Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.

The Korean journal of internal medicine - 1 Mar 2021

Jung Hyun Ae, Jung Chul Won, Jang Jun Ho

Abstract excerpt

BACKGROUND/AIMS: In this study, we tested whether mutations in the methylation pathway genes ten-eleven-translocation 2 (TET2) and DNA methyltransferase gene 3A (DNMT3A) improve the responses of patients with myelodysplastic syndrome (MDS) to decitabine. METHODS: We retrospectively sequenced the TET2 and DNMT3A genes from 70 patients diagnosed with de novo MDS between June 2008 and December 2011 and treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Decitabine
Share to DNA Methylation
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Source

Open in PubMed Open full text

Identifiers

PMID: 33086776
DOI: 10.3904/kjim.2019.385
PMCID: PMC7969079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.PMID 33086776Read ↗

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.Semantic proximity Read ↗

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.Semantic proximity Read ↗

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.Semantic proximity Read ↗

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.Semantic proximity Read ↗

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDSSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabineSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.